

22 October 2026

Syntro Health engaged to advance Stabl-Im clinical trial formulation

- Australian pharmaceutical manufacturing specialist Syntro Health to undertake laboratory formulation activities for the Company's Stabl-Im investigational product
- Engagement represents a further operational milestone in preparation for the Company's planned clinical feasibility study of Stabl-Im
- Syntro Health operates TGA-licensed, current Good Manufacturing Practice (cGMP) facilities and provides specialist investigational medicinal product manufacturing and clinical trial supply services
- Formulation activities will support preparation of Stabl-Im for clinical administration, complementing ongoing analytical method work-up, site selection and clinical study preparation activities
- Planned clinical feasibility study will evaluate the safety, feasibility, pharmacokinetics and reproducibility of systemic deuterium enrichment

Melbourne, Australia: TrivarX Limited ('the Company') (ASX: TRI) is pleased it has entered into an agreement with Australian pharmaceutical manufacturing specialist Syntro Health to undertake laboratory formulation activities for its Stabl-Im imaging platform, representing a further milestone in preparations for the Company's planned clinical trial.

The engagement follows the Company's recent clinical development update (ASX announcement: 23 September 2026), which outlined progress across key workstreams required to advance Stabl-Im into clinical evaluation, including investigational product formulation, analytical methodology development, dosing protocols and clinical study site selection.

Under the agreement, Syntro Health will undertake laboratory formulation activities to support the development of the Stabl-Im investigational product for clinical use.

Syntro Health is an Australian specialist in investigational medicinal product (IMP) manufacturing and management, providing pharmaceutical development, manufacturing, packaging, storage and distribution services for clinical trials. The company operates Therapeutic Goods Administration (TGA)-licensed cGMP facilities and supports pharmaceutical and biotechnology companies undertaking Phase 1 through Phase 4 clinical studies.

The engagement provides TrivarX with access to established pharmaceutical formulation expertise and infrastructure as it progresses the technical and operational requirements for its planned clinical trial.

Stabl-Im is an imaging platform with potential to combine stable isotope technology with magnetic resonance imaging (MRI) to provide insights into cellular activity and metabolism. The technology has the potential to enable non-invasive assessment of disease activity and response to therapy.

The Company's planned feasibility study is designed to assess the safety, feasibility and pharmacokinetics of Stabl-Im, with results intended to inform subsequent clinical development and the potential expansion of the platform into broader applications. The agreement with Syntro Health supports the planned pathway to clinical trials, with first patient enrolment currently scheduled for Q1 2027.

ASX ANNOUNCEMENT



Management commentary:

CEO, Dr Danielle Meyrick said: *"The engagement of Syntro Health represents another important step in advancing Stabl-Im towards clinical evaluation and builds on the progress made across our clinical development program in recent months."*

"Ensuring a suitable formulation for clinical use is an important component of our preparations, and Syntro brings specialist pharmaceutical manufacturing expertise and established infrastructure to support this work."

"We continue to make progress across the technical, clinical and operational activities required to commence our feasibility study. Our focus remains on systematically completing these activities to ensure Stabl-Im is appropriately evaluated in the clinic and to establish a strong foundation for the platform's longer-term development."

This announcement is authorised for release by the Board of Directors of TrivarX Limited.

ENDS

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@sdir.com.au

+61 431 271 538

About TrivarX Limited:

TrivarX Limited (ASX: TRI) is a healthcare technology company focused on developing innovative diagnostic and imaging solutions across mental health and neuro-oncology. The Company's technology suite includes AI-driven algorithms for the detection of mental health conditions using physiological signals, and its Stabl-Im platform, which utilises stable isotope labelling combined with MRI to enable non-invasive imaging of cellular proliferation. Investors can find additional information on www.asx.com.au